Clinical trial
Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients.
NCT00724620 is registered in ClinicalTrials.gov with Schering-Plough as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response and Tolerability, in These Patients.
- Lead sponsor
- Schering-Plough
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- June 30, 2005
- Completion date
- February 29, 2008
- Enrollment
- 103 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.